ReviewThe American journal of drug and alcohol abuse2009
Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.
Review in The American journal of drug and alcohol abuse, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- Association Between Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Methamphetamine Use Disorder: A Meta-Analysis.Frontiers in psychiatry · 2020Pooled it
- Addiction pharmacogenetics: a systematic review of the genetic variation of the dopaminergic system.Psychiatric genetics · 2015Pooled it
- The κ-opioid receptor gene as a predictor of response in a cocaine vaccine clinical trial.Psychiatric genetics · 2013Trial
- Placebo-group responders in methamphetamine pharmacotherapy trials: the role of immediate establishment of abstinence.Experimental and clinical psychopharmacology · 2012Trial
- Rivastigmine reduces "Likely to use methamphetamine" in methamphetamine-dependent volunteers.Progress in neuro-psychopharmacology & biological psychiatry · 2012Trial
- A double-blind, placebo-controlled assessment of the safety of potential interactions between intravenous cocaine, ethanol, and oral disulfiram.Drug and alcohol dependence · 2011Trial
- Cigarette smoking and short-term addiction treatment outcome.Drug and alcohol dependence · 2011Trial
- Individual Variability in Physiological Responses and Psychological Conditions Associated With Methamphetamine Use: Pilot Ecological Momentary Assessment Study Using a Wearable Device and Self-Monitoring Mobile App.JMIR formative research · 2026Article
- PGx-BasedCurrent neuropharmacology · 2026Article
- Genes, Cognition, and Their Interplay in Methamphetamine Use Disorder.Biomolecules · 2025Review
- Dopamine Pharmacodynamics: New Insights.International journal of molecular sciences · 2024Review
- The Effectiveness of Topiramate in the Treatment of Amphetamine and Methamphetamine Use Disorder: A Randomized Controlled Trial.Iranian journal of psychiatry · 2023Article
- Pharmacogenetics of Addiction Therapy.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Aberrant expression ofGeneral psychiatry · 2021Article
- Sex, Drugs, and the Medial Amygdala: A Model of Enhanced Sexual Motivation in the Female Rat.Frontiers in behavioral neuroscience · 2019Article
- Methamphetamine alters DNMT and HDAC activity in the posterior dorsal medial amygdala in an ovarian steroid-dependent manner.Neuroscience letters · 2018Article
- Toward biomarkers of the addicted human brain: Using neuroimaging to predict relapse and sustained abstinence in substance use disorder.Progress in neuro-psychopharmacology & biological psychiatry · 2018Review
- Medications for substance use disorders (SUD): emerging approaches.Expert opinion on emerging drugs · 2017Review
- Clinical features, course and treatment of methamphetamine-induced psychosis in psychiatric inpatients.BMC psychiatry · 2016Article
- Androgen-primed castrate males are sufficient for methamphetamine-facilitated increases in proceptive behavior in female rats.Hormones and behavior · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
backgroundPharmacogenetics uses genetic variation to predict individual differences in response to medications and holds much promise to improve treatment of addictive disorders.
objectivesTo review how genetic variation affects responses to cocaine, amphetamine, and methamphetamine and how this information may guide pharmacotherapy.
methodsWe performed a cross-referenced literature search on pharmacogenetics, cocaine, amphetamine, and methamphetamine.
resultsWe describe functional genetic variants for enzymes dopamine-beta-hydroxylase (DbetaH), catechol-O-methyltransferase (COMT), and dopamine transporter (DAT1), dopamine D4 receptor, and brain-derived neurotrophic factor (BDNF). A single nucleotide polymorphism (SNP; C-1021T) in the DbetaH gene is relevant to paranoia associated with disulfiram pharmacotherapy for cocaine addiction. Individuals with variable number tandem repeats (VNTR) of the SLC6A3 gene 3'-untranslated region polymorphism of DAT1 have altered responses to drugs. The 10/10 repeat respond poorly to methylphenidate pharmacotherapy and the 9/9 DAT1 variant show blunted euphoria and physiological response to amphetamine. COMT, D4 receptor, and BDNF polymorphisms are linked to methamphetamine abuse and psychosis.
conclusionsDisulfiram and methylphenidate pharmacotherapies for cocaine addiction are optimized by considering polymorphisms affecting DbetaH and DAT1 respectively. Altered subjective effects for amphetamine in DAT1 VNTR variants suggest a 'protected' phenotype. SCIENTIFIC SIGNIFICANCE: Pharmacogenetic-based treatments for psychostimulant addiction are critical for successful treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.